Fragile X syndrome: Difference between revisions
Jump to navigation
Jump to search
(4 intermediate revisions by the same user not shown) | |||
Line 37: | Line 37: | ||
== [[Fragile X syndrome natural history, complications and prognosis|Natural History, Complications and Prognosis]] == | == [[Fragile X syndrome natural history, complications and prognosis|Natural History, Complications and Prognosis]] == | ||
== Diagnosis == | == [[Diagnosis]] == | ||
===History and Symptoms=== | ===[[History and Symptoms]]=== | ||
===Physical Examination=== | ===[[Physical Examination]]=== | ||
===Laboratory findings=== | |||
===Other diagnostic studies=== | ===[[Laboratory findings]]=== | ||
===[[Other diagnostic studies]]=== | |||
== Treatment == | == Treatment == |
Revision as of 17:03, 21 October 2021
For patient information click here
Fragile X syndrome | |
Location of FMR1 gene | |
ICD-10 | Q99.2 |
ICD-9 | 759.83 |
OMIM | 309550 |
DiseasesDB | 4973 |
MeSH | D005600 |
Fragile X syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Fragile X syndrome On the Web |
American Roentgen Ray Society Images of Fragile X syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords:: Martin-bell syndrome; marker X syndrome, escalante's syndrome
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Fragile X syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory findings
Other diagnostic studies
Treatment
Medical Therapy | Primary Prevention | Secondary Prevention | Cost Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
External links
Template:Pervasive developmental disorders Template:Chromosomal abnormalities